#USA #Brisbane #Freenome #Exact Sciences #Rob Guigley

Freenome Appoints Rob Guigley as Chief Commercial Officer

In a significant move aimed at enhancing its commercial strategies, Freenome, a pioneering company in early cancer detection through blood-based tests, has appointed the seasoned industry executive Rob Guigley as its Chief Commercial Officer (CCO). This decision comes at a crucial time as the company prepares to expand its market presence, particularly following the recent agreement with Exact Sciences, which has successfully passed antitrust scrutiny.

Rob Guigley brings over two decades of experience in navigating commercial organizations within the healthcare space, including notable positions at Delfi Diagnostics, Invitae, Ambry Genetics, and Omada Health. His expertise is expected to play a pivotal role at Freenome, especially in executing the exclusive licensing agreement with Exact Sciences to commercialize Freenome's blood-based colorectal cancer screening tests. This strategic partnership is geared towards leveraging Exact Sciences' robust commercial infrastructure, ensuring that more patients have access to Freenome's innovative cancer screening solutions.

The Hart-Scott-Rodino Antitrust Improvements Act's waiting period has expired, signaling a crucial step forward for the pending transaction initially announced in August 2025. Furthermore, Freenome's blood test for colorectal cancer, named SimpleScreen™ CRC, is currently under review by the FDA, with anticipated approval in the latter half of 2026.

As Freenome sets its sights on harnessing Guigley's commercial insight, CEO Aaron Elliott emphasized the importance of enhancing their commercial leadership. “Rob Guigley's addition to our team is vital as we aim to maximize the reach of our CRC test while also advancing our multi-cancer pipeline and generating valuable real-world data through commercial testing,” he remarked.

In leading the charge on Freenome's go-to-market strategies, Guigley will focus on strengthening relationships with health systems, ensuring that Freenome’s screening solutions integrate seamlessly into primary care workflows. His experience with utilizing real-world data aligns perfectly with Freenome's vision, enabling them to refine AI and machine learning models that will further enhance cancer detection across various indications.

Beyond colorectal cancer, the company has plans for the second half of 2026 to roll out a laboratory-developed version of its lung cancer screening test. Moreover, Freenome aims to explore over ten additional cancer indications that will inform future assay developments, all backed by extensive patient data from ongoing studies.

Reflecting on his new role, Guigley stated, “What attracted me to Freenome is the blend of rigorous science, validated clinical outcomes, and the advancement of a platform fortified by an expanding data backlog. I am eager to collaborate with Exact Sciences to expedite the availability of SimpleScreen CRC following FDA approval and to fortify Freenome’s commercial framework to reach our innovative multi-cancer test portfolio into the marketplace.”

Freenome’s innovative multiomics platform evaluates a variety of biomarker classes such as epigenomics, transcriptomics, metabolomics, and proteomics, aiming to capture the earliest signs of disease in the bloodstream. The company aims to democratize cancer screenings through the simplicity of a standard blood draw, making early detection more accessible to everyone.

To further its research and market application, Freenome is currently assessing select health systems that will participate in the early access program for SimpleScreen CRC launching in January 2026. The completion of CLIA certification for their laboratory in October 2025 marks a significant milestone, guaranteeing that the lab meets federal standards for reliability and accuracy.

As Freenome propels forward, its mission to transform cancer detection continues to align with collaborations and initiatives designed to integrate state-of-the-art technology with healthcare practices. Freenome's commitment to revolutionizing early cancer detection positions it uniquely in the healthcare landscape, paving the way for more impactful solutions in the future.

For more information about Freenome and their offerings, please visit Freenome and connect with them on LinkedIn.